Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company
March 18, 2022 06:00 ET
|
Apexigen
- Healthcare institutional investors and insiders commit $15 million through private investment in public equity (“PIPE”) - - Lincoln Park Capital has committed to purchase up to $50 million of...
Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer
January 04, 2022 08:00 ET
|
Apexigen
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
Apexigen Announces New Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting
November 12, 2021 08:00 ET
|
Apexigen
- Prolonged tumor response and prolonged disease control were observed in anti-PD(L)-1 refractory melanoma patients treated with sotigalimab in combination with nivolumab - - Biomarker data in...
Apexigen To Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 Melanoma
November 09, 2021 08:00 ET
|
Apexigen
-Webinar to be held Friday, November 19, 2021 at 11:00 a.m. ET- -Featuring Harriet Kluger, M.D., renowned researcher, medical oncologist and lead investigator in the Phase 2 study of sotigalimab in...
Apexigen to Participate in Upcoming Investor Conferences
November 04, 2021 08:00 ET
|
Apexigen
-Stifel Virtual Healthcare Conference-Evercore ISI’s HealthCONx Conference SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company...
Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer
October 06, 2021 08:00 ET
|
Apexigen
SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
Apexigen Announces Presentation of Phase 2 Clinical Data on CD40 Antibody Sotigalimab at the SITC 2021 Annual Meeting
October 01, 2021 08:05 ET
|
Apexigen
SAN CARLOS, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
Apexigen Announces Appointment of Dr. Frank Hsu as Chief Medical Officer
September 09, 2021 08:00 ET
|
Apexigen
SAN CARLOS, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
Apexigen to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 08:00 ET
|
Apexigen
SAN CARLOS, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...
Apexigen Receives Orphan Drug Designation from the FDA for Sotigalimab (APX005M) for the Treatment of Soft Tissue Sarcoma
August 05, 2021 08:00 ET
|
Apexigen
SAN CARLOS, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...